title: [Chemoprevention of breast cancer by tamoxifen: should we still ask this question?].
abstract: Pharmacoprevention of cancer is an attractive concept. For breast cancer, several trials were set up some years ago. The largest one was stopped before its planned date of closure and demonstrated an early appearing reduction in breast cancer occurrence; in contrast, the other two trials did not find such a protective effect. The decision is all the more difficult because of tamoxifen side effects, including carcinogenicity. Currently, no definite conclusion can be drawn.
authors.affiliation: Unité d'Epidémiologie pour la Prévention du Cancer, Centre International de Recherche sur le Cancer, Lyon.
authors.forename: A J
authors.initials: AJ
authors.lastname: Sasco
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007558:Italy; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States
chemical_list: D016588:Anticarcinogenic Agents; D013629:Tamoxifen
vernacular_title: Pharmacoprévention du cancer du sein par tamoxifène: devons-nous encore nous poser la question?